Prognostic and Predictive Value of Tumor Budding in Colorectal Cancer
Clinical Colorectal Cancer · 2021-09 · 20 (3) · 256-264
DOI: 10.1016/j.clcc.2021.05.003 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Colorectal Cancer, 2021-09. Verfasst von Bojana Mitrovic und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Health Sciences North, Sudbury, ON, Canada; University of Toronto, Toronto, Canada. Electronic addre…. Hauptthemen laut MEDLINE: Colorectal Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Tumor budding (TB) is an adverse prognostic factor in colorectal cancer (CRC). International consensus on a standardized assessment method has led to its wider reporting. However, uncertainty regarding its clinical value persists. This study aimed to (1) confirm the prognostic significance of TB, particularly in stage II CRC; (2) to determine optimum thresholds for TB risk grouping; and (3) to determine whether TB influences responsiveness to chemotherapy. METHODS: TB was assessed in CRC sections from 1575 QUASAR trial patients randomized between adjuvant chemotherapy and observation. Optimal risk group cutoffs were determined by maximum likelihood methods, with their influence on recurrence and mortality investigated in stratified log-rank analyses on exploratory (n = 504), hypothesis-testing (n = 478), and final (n = 593) data sets. RESULTS: The optimal threshold for high-grade TB (HGTB) was ≥ 10 buds per 1.23 mm2. High-grade TB tumors had significantly worse outcomes than those with lower TB: 10-year recurrence 36% versus 22% (risk ratio, 2.00 [95% CI, 1.62-2.45]; 2P < .0001) and 10-year mortality 50% vs. 37% (risk ratio, 1.53 [95% CI, 1.34-1.76]; 2P < .0001). The prognostic significance remained equally strong after allowance for other pathological risk factors, including stage, grade, lymphovascular invasion, and mismatch repair status. There was a nonsignificant trend toward increasing chemotherapy efficacy with increasing bud counts. CONCLUSIONS: TB is a strong independent predictor of recurrence. Chemotherapy efficacy is comparable in patients with higher and lower TB; hence, absolute reductions in recurrence and death with chemotherapy should be about twice as large in patients with ≥ 10 than < 10 TB counts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Health Sciences North, Sudbury, ON, Canada; University of Toronto, Toronto, Canada. Electronic address: bojana.mitrovic@utoronto.ca.
- Birmingham Clinical Trials Unit, Birmingham, United Kingdom.
- University of Toronto, Toronto, Canada.
- Section of Pathology and Tumour Biology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom.
- University of Toronto, Toronto, Canada; Mount Sinai Hospital, Toronto, ON, Canada.
- Clinical Trial Service Unit & Epidemiological Studies, University of Oxford, United Kingdom.
Zitieren
APA
Mitrovic, B., Handley, K., Assarzadegan, N., Chang, H. L., Dawson, H. A. E., Grin, A., Hutchins, G. G. A., Magill, L., Quirke, P., Riddell, R. H., Gray, R. G., Kirsch, R., & QUASAR Collaborative Group (2021). Prognostic and Predictive Value of Tumor Budding in Colorectal Cancer. Clinical Colorectal Cancer, 20(3), 256-264. https://doi.org/10.1016/j.clcc.2021.05.003
Vancouver
Mitrovic B, Handley K, Assarzadegan N, Chang HL, Dawson HAE, Grin A, et al. Prognostic and Predictive Value of Tumor Budding in Colorectal Cancer. Clinical Colorectal Cancer. 2021;20(3):256-264. doi:10.1016/j.clcc.2021.05.003
BibTeX
@article{Mitrovic2021,
author = {Mitrovic, Bojana and Handley, Kelly and Assarzadegan, Naziheh and Chang, Hector Li and Dawson, Heather A E and Grin, Andrea and Hutchins, Gordon G A and Magill, Laura and Quirke, Philip and Riddell, Robert H and Gray, Richard G and Kirsch, Richard and QUASAR Collaborative Group, QUASAR Collaborative Group},
title = {Prognostic and Predictive Value of Tumor Budding in Colorectal Cancer},
journal = {Clinical Colorectal Cancer},
year = {2021},
volume = {20},
number = {3},
pages = {256--264},
doi = {10.1016/j.clcc.2021.05.003}
}
EUVIMED